Research & Development
Serum Institute of India gets regulatory approval to resume Indian trial of AstraZeneca COVID vaccine
16 September 2020 -

Reuters news agency reported on Wednesday that according to a source, Serum Institute of India has received Indian regulatory approval, from the Drugs Controller General of India, to resume local clinical trials of British pharmaceutical company AstraZeneca's potential COVID-19 vaccine.

Reportedly, AstraZeneca has resumed British clinical trials of the vaccine, considered one of the most advanced in development for COVID-19, after they were paused earlier this month following a serious side effect in a trial participant.

Trials have also resumed in Brazil and South Africa.

However, the trial remains on hold in the US, as confirmed by the US Food and Drug Administration on 15 September 2020.



Related Headlines